Recent RNA News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 10:21:48 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 10:15:29 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/15/2024 01:10:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 01:09:02 PM
- Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors • PR Newswire (US) • 05/15/2024 01:00:00 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 05/09/2024 08:22:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:13:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:07:15 PM
- Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights • PR Newswire (US) • 05/09/2024 08:05:00 PM
- Avidity Biosciences to Participate in Upcoming Investor Conference • PR Newswire (US) • 05/08/2024 08:05:00 PM
- Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1 • PR Newswire (US) • 05/08/2024 10:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2024 01:52:58 AM
- Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 04/22/2024 08:05:00 PM
- Avidity Biosciences to Participate in Upcoming Investor Conferences • PR Newswire (US) • 03/27/2024 01:00:00 PM
- Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 03/21/2024 08:05:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 09:23:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:53:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 12:07:00 PM
- Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial • PR Newswire (US) • 03/04/2024 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 09:31:50 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/29/2024 09:19:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:06:10 PM
- Avidity Biosciences Honors Rare Disease Day® • PR Newswire (US) • 02/29/2024 05:00:00 PM
- Avidity Biosciences Announces Oversubscribed $400 Million Private Placement • PR Newswire (US) • 02/29/2024 12:00:00 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 02/28/2024 10:32:43 PM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM